141 related articles for article (PubMed ID: 34133388)
1. Isolated Bone Recurrence of Medulloblastoma With MYCN Amplification and TP53 Loss: A Case Report.
Takahashi Y; Kudo K; Ogawa K; Sato T; Kamio T; Sasaki S; Kobayashi A; Ito T; Yamamoto T; Asano K; Ohkuma H; Kurose A; Ito E; Terui K
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e593-e596. PubMed ID: 34133388
[TBL] [Abstract][Full Text] [Related]
2. Clinical Aggressiveness of TP53-Wild Type Sonic Hedgehog Medulloblastoma With MYCN Amplification, Chromosome 17p Loss, and Chromothripsis.
Mitani Y; Fukuoka K; Mori M; Arakawa Y; Matsushita Y; Hibiya Y; Honda S; Kobayashi M; Tanami Y; Kanemura Y; Ichimura K; Nakazawa A; Kurihara J; Koh K
J Neuropathol Exp Neurol; 2021 Jan; 80(2):205-207. PubMed ID: 33367701
[No Abstract] [Full Text] [Related]
3. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
4. TP53 Mutation, MYCN Amplification, and Large Cell/Anaplastic Histology in Medulloblastoma.
Das A; Zameer L; Vinarkar S; Singh M; Parihar M; Arora N; Chandra A; Achari RB
Indian J Pediatr; 2018 Aug; 85(8):684-685. PubMed ID: 29139064
[No Abstract] [Full Text] [Related]
5. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.
Aldosari N; Bigner SH; Burger PC; Becker L; Kepner JL; Friedman HS; McLendon RE
Arch Pathol Lab Med; 2002 May; 126(5):540-4. PubMed ID: 11958658
[TBL] [Abstract][Full Text] [Related]
6. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of medulloblastoma in children under age of three years.
Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
9. A case of molecularly profiled extraneural medulloblastoma metastases in a child.
Mobark NA; Al-Harbi M; Mosleh O; Santagata S; Snuderl M; Abedalthagafi M
BMC Med Genet; 2018 Jan; 19(1):10. PubMed ID: 29343221
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma with multi-lineage differentiation including myogenic and melanotic elements: a case report with molecular data.
Stefanits H; Ebetsberger-Dachs G; Weis S; Haberler C
Clin Neuropathol; 2014; 33(2):122-7. PubMed ID: 24131750
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas.
Lindsey JC; Hill RM; Megahed H; Lusher ME; Schwalbe EC; Cole M; Hogg TL; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(12):e344-6; author reply e347-8. PubMed ID: 21357788
[No Abstract] [Full Text] [Related]
12. Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.
Moreno DA; da Silva LS; Zanon MF; Bonatelli M; de Paula FE; de Medeiros Matsushita M; Teixeira GR; Santana IVV; Saggioro F; Neder L; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Garcia-Rivello H; Christiansen S; Nunes S; da Costa MJG; Soares MJ; Pinheiro J; Junior CA; Mançano BM; Reis RM
J Neurooncol; 2022 Mar; 157(1):27-35. PubMed ID: 35166989
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia.
Alassiri AH; Alsufiani FM; Almutairi AA; Almohini IA; Aldosari MA; Essa MF
Neurosciences (Riyadh); 2020 Jul; 25(3):218-221. PubMed ID: 32683405
[TBL] [Abstract][Full Text] [Related]
14. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
16. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
17. Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization.
Jay V; Squire J; Bayani J; Alkhani AM; Rutka JT; Zielenska M
Pathology; 1999 Nov; 31(4):337-44. PubMed ID: 10643003
[TBL] [Abstract][Full Text] [Related]
18. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
19. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
20. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]